Tag: delmar pharmaceuticals

Big News Roundup: Relay Medical To Commence Trading in United States as RYMDF; BriaCell Announces Positive Phase IIa Proof of Concept Data in Advanced Breast Cancer; Initiates Combination Study; Kalytera Announces Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

In case you missed it, here is this week's big news roundup in the Life Science sector.

8 Glioblastoma Treatment Stocks

With an average survival rate of 16 months, glioblastoma is the most common and deadly type of brain cancer, accounting...

Investing in Glioblastoma Treatments

Glioblastoma tumors are one of the most aggressive forms of cancer and yet have very few treatments. Here's how investing...

DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new...

DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, today provided...

DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results

DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) has announced financial results for Q1 ended September 30, 2017. The Company also announced a business...

DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer

DelMar Pharmaceuticals, Inc. (Nasdaq:DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today...